BR112014016550A2 - formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma - Google Patents
formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesmaInfo
- Publication number
- BR112014016550A2 BR112014016550A2 BR112014016550A BR112014016550A BR112014016550A2 BR 112014016550 A2 BR112014016550 A2 BR 112014016550A2 BR 112014016550 A BR112014016550 A BR 112014016550A BR 112014016550 A BR112014016550 A BR 112014016550A BR 112014016550 A2 BR112014016550 A2 BR 112014016550A2
- Authority
- BR
- Brazil
- Prior art keywords
- release formulation
- delayed release
- urination frequency
- subject
- pharmaceutical composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000003111 delayed effect Effects 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 230000036318 urination frequency Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 239000000730 antalgic agent Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
resumo formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma métodos e composições para reduzir a frequência de urinação são revelados. um método compreende administrar a um sujeito com essa necessidade uma quantidade eficaz de uma composição farmacêutica que compreende um agente analgésico formulado em uma formulação de liberação retardada. outro método compreende administrar a um sujeito com essa necessidade uma quantidade eficaz de uma composição farmacêutica que compreende múltiplos ingredientes ativos. ainda outro método compreende administrar a um sujeito com essa necessidade uma quantidade eficaz de um diurético seguida com outra administração de uma composição farmacêutica que compreende um agente analgésico.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/343,349 US20120141554A1 (en) | 2010-07-08 | 2012-01-04 | Delayed release formulation for reducing the frequency of urination and method of use thereof |
US13/423,949 US8236856B2 (en) | 2010-07-08 | 2012-03-19 | Delayed release formulation for reducing the frequency of urination and method of use thereof |
US13/487,343 US20120237574A1 (en) | 2010-07-08 | 2012-06-04 | Delayed-release formulation for reducing the frequency of urination and method of use thereof |
PCT/US2012/051859 WO2013103389A1 (en) | 2012-01-04 | 2012-08-22 | Delayed-release formulation for reducing the frequency of urination and method of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014016550A2 true BR112014016550A2 (pt) | 2017-06-13 |
BR112014016550A8 BR112014016550A8 (pt) | 2017-07-04 |
Family
ID=48745354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014016550A BR112014016550A8 (pt) | 2012-01-04 | 2012-08-22 | formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma |
Country Status (12)
Country | Link |
---|---|
US (2) | US8703184B2 (pt) |
JP (3) | JP2015506359A (pt) |
KR (3) | KR20180023057A (pt) |
AU (1) | AU2012363788B2 (pt) |
BR (1) | BR112014016550A8 (pt) |
CA (1) | CA2856673C (pt) |
IL (1) | IL232711A0 (pt) |
MX (1) | MX2014008284A (pt) |
RU (1) | RU2597156C2 (pt) |
SG (1) | SG11201500410XA (pt) |
WO (1) | WO2013103389A1 (pt) |
ZA (1) | ZA201403762B (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130323288A1 (en) | 2010-07-08 | 2013-12-05 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for bedwetting and method of use thereof |
US9532959B2 (en) | 2010-07-08 | 2017-01-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US10010514B2 (en) | 2010-07-08 | 2018-07-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US10278925B2 (en) * | 2012-01-04 | 2019-05-07 | Wellesley Pharmaceuticals, Llc | Delayed-release formulations, methods of making and use thereof |
US10105330B2 (en) | 2012-01-04 | 2018-10-23 | Wellesley Pharmaceuticals, Llc | Extended, delayed and immediate release formulation method of manufacturing and use thereof |
US10792326B2 (en) | 2013-06-28 | 2020-10-06 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for bedwetting and method of use thereof |
WO2016041036A1 (pt) * | 2014-09-19 | 2016-03-24 | Diffucap Chemobras Química E Farmacéutical Ltda | Combinação farmacêutica contendo um agente analgésico e um agente antiespasmódico |
US10105328B2 (en) | 2014-06-06 | 2018-10-23 | Wellesley Pharmaceuticals, Llc | Composition for reducing frequency of urination, method of making and use thereof |
RU2016152226A (ru) * | 2014-06-06 | 2018-07-09 | УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения |
RU2018111401A (ru) * | 2015-09-01 | 2019-10-02 | УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Составы с отсроченным высвобождением, способы их получения и применения |
KR20180054655A (ko) * | 2015-09-01 | 2018-05-24 | 웰즐리 파마슈티컬스 엘엘씨 | 연장, 지연 및 즉시 방출 제형 제조 방법 및 용도 |
KR102314838B1 (ko) | 2021-04-01 | 2021-10-19 | 송관권 | 터널 비개착공법 |
KR102364887B1 (ko) | 2021-06-14 | 2022-02-18 | 송관권 | 터널 비개착 일체식 압입공법 및 그에 적용되는 일체식 가설구조물 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0818971B2 (ja) * | 1989-02-16 | 1996-02-28 | ブリティッシュ・テクノロジー・グループ・リミテッド | 投与製剤 |
DE69226624T3 (de) * | 1991-09-06 | 2009-11-05 | Ortho-Mcneil Pharmaceutical, Inc. | Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung |
WO1998046216A1 (fr) * | 1997-04-11 | 1998-10-22 | Nippon Shinyaku Co., Ltd. | Traitements des mictions frequentes et de l'incontinence urinaire |
AU2546399A (en) * | 1998-02-10 | 1999-08-30 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations with controlled release |
US7138393B2 (en) * | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
WO2001017480A2 (en) | 1999-09-09 | 2001-03-15 | Androsolutions, Inc. | Methods and compositions for preventing and treating urinary tract disorders |
WO2002019213A2 (en) | 2000-08-30 | 2002-03-07 | Lilly Icos Llc | Method for treatment of migraine using pde5 inhibitors |
RU2193401C1 (ru) * | 2001-04-02 | 2002-11-27 | Аль-Шукри Салман Хасунович | Способ лечения гиперактивности мочевого пузыря |
EP1437344A4 (en) | 2001-09-28 | 2006-09-20 | Takeda Pharmaceutical | BENZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
WO2003043655A1 (fr) * | 2001-11-19 | 2003-05-30 | Ono Pharmaceutical Co., Ltd. | Remedes pour la frequence urinaire |
PL372395A1 (en) * | 2002-02-19 | 2005-07-25 | Pharmacia Corporation | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
CA2489398A1 (en) * | 2002-07-08 | 2004-01-15 | Pliva-Istrazivacki Institut D.O.O. | Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
US7582651B2 (en) | 2002-07-11 | 2009-09-01 | Takeda Pharmaceutical Company Limited | Pyrrolopyridine derivative and use thereof |
US20050152905A1 (en) * | 2002-08-22 | 2005-07-14 | Omoigui Osemwota S. | Method of biochemical treatment of persistent pain |
US20040054008A1 (en) * | 2002-09-13 | 2004-03-18 | Tohru Araki | Medicament for treatment of nocturia |
AU2003271024A1 (en) * | 2002-09-21 | 2004-04-08 | Jin Wang | Sustained release compound of acetamidophenol and tramadol |
DE602004003172T2 (de) * | 2003-03-21 | 2007-09-27 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals |
US20040186180A1 (en) * | 2003-03-21 | 2004-09-23 | Gelotte Cathy K. | Non-steroidal anti-inflammatory drug dosing regimen |
US8029822B2 (en) | 2003-05-22 | 2011-10-04 | Osmotica Kereskedelmi és Seolgáltató KFT | Rupturing controlled release device having a preformed passageway |
US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
DE10356112A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff |
EP1627876A1 (en) * | 2004-08-20 | 2006-02-22 | Ferring B.V. | Heterocyclic condensed compounds useful as antidiuretic agents |
CA2646729A1 (en) | 2005-03-21 | 2006-09-28 | Dov Pharmaceutical, Inc. | Methods and compositions for the treatment of urinary incontinence |
EP1741444A1 (en) * | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
US20080166407A1 (en) | 2005-07-29 | 2008-07-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
WO2007072503A2 (en) * | 2005-12-21 | 2007-06-28 | Panacea Biotec Ltd. | Combinations for managing inflammation and associated disorders |
WO2007083323A2 (en) | 2006-01-23 | 2007-07-26 | Panacea Biotec Limited. | Modified release oral dosage form comprising desmopressin |
CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
US20090069275A1 (en) | 2006-02-17 | 2009-03-12 | Rocca Jose G | Low flush niacin formulation |
US20070237816A1 (en) * | 2006-04-06 | 2007-10-11 | David Finkelstein | Acetaminophen formulation for joint pain relief |
WO2008014175A2 (en) | 2006-07-28 | 2008-01-31 | Dr. Reddy's Laboratories Ltd. | Granular pharmaceutical compositions |
EP2054055A2 (en) * | 2006-08-18 | 2009-05-06 | N.V. Organon | Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent |
US20080057122A1 (en) * | 2006-08-31 | 2008-03-06 | Aaipharma Inc. | Acetaminophen pharmaceutical compositions |
CA2988753A1 (en) | 2007-08-06 | 2009-02-12 | Serenity Pharmaceuticals, Llc | Methods and devices for desmopressin drug delivery |
WO2010138441A1 (en) * | 2009-05-28 | 2010-12-02 | Aptapharma, Inc. | Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen |
GB201003731D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
US20120135050A1 (en) | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
-
2012
- 2012-08-22 KR KR1020187005475A patent/KR20180023057A/ko active Application Filing
- 2012-08-22 KR KR1020147018674A patent/KR20140108674A/ko active Application Filing
- 2012-08-22 RU RU2014131238/15A patent/RU2597156C2/ru not_active IP Right Cessation
- 2012-08-22 KR KR1020197012474A patent/KR20190049928A/ko not_active Application Discontinuation
- 2012-08-22 MX MX2014008284A patent/MX2014008284A/es unknown
- 2012-08-22 CA CA2856673A patent/CA2856673C/en not_active Expired - Fee Related
- 2012-08-22 WO PCT/US2012/051859 patent/WO2013103389A1/en active Application Filing
- 2012-08-22 AU AU2012363788A patent/AU2012363788B2/en not_active Ceased
- 2012-08-22 SG SG11201500410XA patent/SG11201500410XA/en unknown
- 2012-08-22 JP JP2014551233A patent/JP2015506359A/ja active Pending
- 2012-08-22 BR BR112014016550A patent/BR112014016550A8/pt not_active Application Discontinuation
-
2013
- 2013-03-20 US US13/847,940 patent/US8703184B2/en not_active Expired - Fee Related
-
2014
- 2014-02-07 US US14/175,183 patent/US20140154314A1/en not_active Abandoned
- 2014-05-20 IL IL232711A patent/IL232711A0/en unknown
- 2014-05-22 ZA ZA2014/03762A patent/ZA201403762B/en unknown
-
2017
- 2017-02-02 JP JP2017017179A patent/JP2017122091A/ja active Pending
-
2018
- 2018-11-16 JP JP2018215136A patent/JP2019055969A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20140108674A (ko) | 2014-09-12 |
JP2015506359A (ja) | 2015-03-02 |
ZA201403762B (en) | 2015-10-28 |
AU2012363788A2 (en) | 2014-07-24 |
BR112014016550A8 (pt) | 2017-07-04 |
KR20180023057A (ko) | 2018-03-06 |
JP2017122091A (ja) | 2017-07-13 |
AU2012363788B2 (en) | 2017-03-09 |
US20140154314A1 (en) | 2014-06-05 |
CA2856673C (en) | 2018-08-21 |
SG11201500410XA (en) | 2015-04-29 |
WO2013103389A1 (en) | 2013-07-11 |
JP2019055969A (ja) | 2019-04-11 |
CA2856673A1 (en) | 2013-07-11 |
US20130224291A1 (en) | 2013-08-29 |
US8703184B2 (en) | 2014-04-22 |
RU2597156C2 (ru) | 2016-09-10 |
MX2014008284A (es) | 2015-03-03 |
IL232711A0 (en) | 2014-07-31 |
KR20190049928A (ko) | 2019-05-09 |
AU2012363788A1 (en) | 2014-07-17 |
RU2014131238A (ru) | 2016-02-20 |
NZ626622A (en) | 2016-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014016550A8 (pt) | formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma | |
BR112014016661A2 (pt) | formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma | |
ECSP11011278A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
BR112012010083B8 (pt) | Composição farmacêutica tópica de liberação sustentada e uso relacionado | |
CL2016000882A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15). | |
BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
BR112012023021A2 (pt) | compostos de indazol e seus usos | |
BR112014027204A2 (pt) | conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos | |
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
CL2015002433A1 (es) | Imidazopiridazinas sustituidas | |
BR112015021112A2 (pt) | composições farmacêuticas que compreendem everolimo | |
NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
MX357704B (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
BR112015022117A2 (pt) | precursor da composição cosmética, composição cosmética para a aplicação tópica, método para a administração de um agente cosmético sólido e amida de triciclodecano | |
MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
BR112013025610A2 (pt) | uso de um metapneumovírus aviário vivo, e, composição farmacêutica | |
DOP2015000127A (es) | Formulación farmacéutica de n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il] benzamida | |
BR112014018426A8 (pt) | Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina | |
CL2015001368A1 (es) | Metodo para anticoncepcion controlada que comprende administrar una preparacion farmaceutica que comprende levonorgestrel y un inhibidor de la cox; uso de la composicion farmaceutica en la anticoncepcion "a la carta". | |
ECSP12012332A (es) | Asociación de inhibidores de la xantina oxidasa y la instatina y su uso | |
AR086252A1 (es) | Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo | |
CO6630144A2 (es) | Asociación de inhibidores de la xantina oxidasa y la instatina y su uso | |
FR2971941B1 (fr) | Compositions pharmaceutiques administrables par voie cutanee et destinees au traitement local de la dermatite atopique canine | |
AR063816A1 (es) | Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |